Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a Partially Double-blinded, Multi-center, Randomized, Controlled Superiority Study

NCT05658172 is registered in ClinicalTrials.gov with Prof. Wolfgang Janni as lead sponsor.

NCT NCT05658172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05658172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a Partially Double-blinded, Multi-center, Randomized, Controlled Superiority Study
Lead sponsor
Prof. Wolfgang Janni
Phase
Not applicable
Overall status
Recruiting
Start date
December 7, 2022
Completion date
December 31, 2035
Enrollment
3,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer